CR20210077A - Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa - Google Patents

Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa

Info

Publication number
CR20210077A
CR20210077A CR20210077A CR20210077A CR20210077A CR 20210077 A CR20210077 A CR 20210077A CR 20210077 A CR20210077 A CR 20210077A CR 20210077 A CR20210077 A CR 20210077A CR 20210077 A CR20210077 A CR 20210077A
Authority
CR
Costa Rica
Prior art keywords
heterocyclic compounds
new heterocyclic
lipase inhibitors
monoacylglycerol lipase
compounds
Prior art date
Application number
CR20210077A
Other languages
English (en)
Inventor
Joerg Benz
Martin Ritter
Carsten Kroll
Hans Richter
Martin Kuratli
Didier Rombach
Bernd Kuhn
Uwe Grether
Marius Daniel Rinaldo Lutz
Benoit Hornsperger
Zbinden Katrin Groebke
Buelent Kocer
Fionn O`Hara
Charles Bell
Luca Gobbi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20210077A publication Critical patent/CR20210077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

<p>La invención proporciona nuevos compuestos heterocíclicos que presentan la fórmula general (I) en donde A, L, X, m, n, R1 y R2 son como se describe en la presente, composiciones que incluyen los compuestos, procesos de fabricación de los compuestos y métodos de utilización de los compuestos.</p>
CR20210077A 2018-08-13 2019-08-12 Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa CR20210077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18188681 2018-08-13
PCT/EP2019/071520 WO2020035424A1 (en) 2018-08-13 2019-08-12 New heterocyclic compounds as monoacylglycerol lipase inhibitors

Publications (1)

Publication Number Publication Date
CR20210077A true CR20210077A (es) 2021-03-11

Family

ID=63244467

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210077A CR20210077A (es) 2018-08-13 2019-08-12 Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa

Country Status (22)

Country Link
US (3) US20200308190A1 (es)
EP (1) EP3837263A1 (es)
JP (1) JP2021534139A (es)
KR (1) KR20210045992A (es)
CN (1) CN112867720A (es)
AR (1) AR116666A1 (es)
AU (1) AU2019322538B2 (es)
BR (1) BR112021002298A2 (es)
CA (1) CA3104928A1 (es)
CL (1) CL2021000362A1 (es)
CO (1) CO2021002382A2 (es)
CR (1) CR20210077A (es)
IL (1) IL279173A (es)
MA (1) MA53219A (es)
MX (1) MX2021001433A (es)
PE (1) PE20211089A1 (es)
PH (1) PH12021500013A1 (es)
RU (1) RU2769507C1 (es)
SG (1) SG11202013064WA (es)
TW (1) TWI812770B (es)
UA (1) UA127629C2 (es)
WO (1) WO2020035424A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
EP3717477B1 (en) 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG New heterocyclic compounds
JP7269943B2 (ja) 2018-01-08 2023-05-09 エフ． ホフマン－ラ ロシュ アーゲー Ｍａｇｌ阻害剤としてのオクタヒドロピリド［１，２－アルファ］ピラジン
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
MX2021001433A (es) 2018-08-13 2021-04-12 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
KR20220058553A (ko) * 2019-09-05 2022-05-09 루난 파마슈티컬 그룹 코퍼레이션 Magl 억제제 및 이의 제조 방법, 용도
US20210094971A1 (en) * 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
CN114269755A (zh) 2019-09-12 2022-04-01 豪夫迈·罗氏有限公司 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物
KR20220066894A (ko) * 2019-09-23 2022-05-24 에프. 호프만-라 로슈 아게 헤테로사이클릭 화합물
AR120030A1 (es) * 2019-09-24 2022-01-26 Hoffmann La Roche Compuestos heterocíclicos
AR120029A1 (es) * 2019-09-24 2022-01-26 Hoffmann La Roche Compuestos heterocíclicos
MX2022004128A (es) * 2019-10-07 2022-06-16 De Shaw Res Llc Compuestos heterociclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3.
EP4126825A1 (en) * 2020-03-26 2023-02-08 Janssen Pharmaceutica NV Aminocyclobutanes as monoacylglycerol lipase modulators

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214038A (en) 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
EP1863483A4 (en) 2005-03-31 2010-03-31 Janssen Pharmaceutica Nv Bicyclic pyrazole compounds as anti-bacteriostatic agents
ES2337728T3 (es) 2005-06-20 2010-04-28 Schering Corporation Piperidinas sustituidas unidas a carbono y sus derivados utiles como antagonistas de histamina h3.
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7696229B2 (en) 2006-02-17 2010-04-13 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
WO2007117557A2 (en) 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
CA2679754C (en) 2007-03-12 2018-08-07 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
AU2009309869A1 (en) 2008-10-29 2010-05-06 F. Hoffmann-La Roche Ag Novel phenyl amide or pyridil amide derivatives and their use as GPBAR1 agonists
WO2011029804A1 (en) 2009-09-10 2011-03-17 F. Hoffmann-La Roche Ag Inhibitors of jak
WO2011059118A1 (ko) 2009-11-10 2011-05-19 Kim Hyun Jeen 후각인지능력 검사 시스템
US9051296B2 (en) * 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
WO2012155199A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
WO2013059118A1 (en) 2011-10-19 2013-04-25 The Trustees Of Columbia University In The City Of New York Cyclopropenimine catalyst compositions and processes
WO2013080156A1 (en) 2011-11-30 2013-06-06 Actelion Pharmaceuticals Ltd 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
AP4055A (en) 2011-12-22 2017-03-07 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
MX350788B (es) 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
ES2640482T3 (es) 2013-04-16 2017-11-03 Idorsia Pharmaceuticals Ltd Derivados biaromáticos antibacterianos
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US10106556B2 (en) 2015-03-30 2018-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3294729A1 (en) 2015-05-13 2018-03-21 Selvita S.A. Substituted quinoxaline derivatives
JP6703553B2 (ja) 2015-05-21 2020-06-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｐａｄ４阻害剤としてのベンゾイミダゾール誘導体
ES2849951T3 (es) 2015-06-18 2021-08-24 89Bio Ltd Derivados de piperidina 4-bencil y 4-benzoil sustituidos
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
WO2017087863A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
PE20190409A1 (es) 2016-03-31 2019-03-14 Takeda Pharmaceuticals Co Compuesto heterociclico
WO2017170830A1 (ja) 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物
AU2017289318A1 (en) 2016-06-30 2018-11-29 Basilea Pharmaceutica International AG Mitochondrial inhibitors for the treatment of proliferation disorders
AU2018285131B2 (en) 2017-06-12 2021-11-11 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors
AU2018338855B2 (en) 2017-09-29 2022-04-28 Takeda Pharmaceutical Company Limited Heterocyclic compound
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
EP3717477B1 (en) 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG New heterocyclic compounds
TW201930300A (zh) 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
JP7269943B2 (ja) 2018-01-08 2023-05-09 エフ． ホフマン－ラ ロシュ アーゲー Ｍａｇｌ阻害剤としてのオクタヒドロピリド［１，２－アルファ］ピラジン
TWI818967B (zh) 2018-03-22 2023-10-21 瑞士商赫孚孟拉羅股份公司 新穎雜環化合物
MX2021001433A (es) 2018-08-13 2021-04-12 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
AU2019322161A1 (en) 2018-08-13 2020-11-12 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
SI3883936T1 (sl) 2018-11-22 2023-10-30 F. Hoffmann - La Roche Ag Nove heterociklične spojine
AU2019382642A1 (en) 2018-11-22 2021-06-10 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CN113767105A (zh) 2019-04-09 2021-12-07 豪夫迈·罗氏有限公司 作为单酰基甘油脂肪酶(magl)的抑制剂的杂环化合物
EP3994137A1 (en) 2019-07-03 2022-05-11 F. Hoffmann-La Roche AG Heterocyclic monoacylglycerol lipase (magl) inhibitors
JP2022539604A (ja) 2019-07-09 2022-09-12 エフ．ホフマン－ラ ロシュ アーゲー 新規複素環化合物
US20210094971A1 (en) 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
CN114269755A (zh) 2019-09-12 2022-04-01 豪夫迈·罗氏有限公司 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物
CN114650994A (zh) 2019-09-12 2022-06-21 豪夫迈·罗氏有限公司 放射性标记的化合物
KR20220066894A (ko) 2019-09-23 2022-05-24 에프. 호프만-라 로슈 아게 헤테로사이클릭 화합물
JP2022549306A (ja) 2019-09-24 2022-11-24 エフ．ホフマン－ラ ロシュ アーゲー モノアシルグリセロールリパーゼ（ｍａｇｌ）の蛍光プローブ
AR120030A1 (es) 2019-09-24 2022-01-26 Hoffmann La Roche Compuestos heterocíclicos
AR120029A1 (es) 2019-09-24 2022-01-26 Hoffmann La Roche Compuestos heterocíclicos

Also Published As

Publication number Publication date
AU2019322538A1 (en) 2021-01-07
EP3837263A1 (en) 2021-06-23
AU2019322538B2 (en) 2021-09-30
US20240150373A1 (en) 2024-05-09
PE20211089A1 (es) 2021-06-14
TW202021970A (zh) 2020-06-16
RU2769507C1 (ru) 2022-04-01
MA53219A (fr) 2021-11-17
AR116666A1 (es) 2021-06-02
JP2021534139A (ja) 2021-12-09
CO2021002382A2 (es) 2021-03-08
KR20210045992A (ko) 2021-04-27
TWI812770B (zh) 2023-08-21
CL2021000362A1 (es) 2021-07-09
US20200308190A1 (en) 2020-10-01
SG11202013064WA (en) 2021-01-28
IL279173A (en) 2021-01-31
CA3104928A1 (en) 2020-02-20
UA127629C2 (uk) 2023-11-08
US20230050901A1 (en) 2023-02-16
CN112867720A (zh) 2021-05-28
PH12021500013A1 (en) 2021-09-13
MX2021001433A (es) 2021-04-12
US11802133B2 (en) 2023-10-31
BR112021002298A2 (pt) 2021-05-04
WO2020035424A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
CR20210077A (es) Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
PH12021500015A1 (en) New heterocyclic compounds as monoacylglycerol lipase inhibitors
PH12021551167A1 (en) New heterocyclic compounds
CR20200416A (es) Nuevos compuestos heterocíclicos
MX2022002711A (es) Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl).
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
MX2022002311A (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
PH12019500664A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
CR20220117A (es) Compuestos heterocíclicos
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MX2022002554A (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
MX2022003023A (es) Compuestos heterociclicos.
MX2022000243A (es) Nuevos compuestos heterociclicos.
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
MX2013009388A (es) Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl).
WO2018102256A8 (en) Pyrrolidinone compounds
PH12021550320A1 (en) Bicyclic heteroaryl derivatives
CR20210614A (es) Nuevos inhibidores de egfr
PH12018500406A1 (en) Bicyclic compounds as atx inhibitors